Company Overview of Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited develops, manufactures, and markets various pharmaceutical products worldwide. It provides calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology under the Asomex, Metpure, S-Numlo, Eslo, Lomoh, Elaxim, Velix, and Atorec brands; haematinics and iron combinations, progestogen, and simi combinations for gynecology under the brand names of Orofer-XT, Orofer-S, Encicarb, Ferium-XT, and Feronia-XT; and anti-infective products comprising cephalosporins and ampicillin under the Zostum, Merotec, Netromax, and Augpen brand names. The company also offers vitamins, minerals, and nutrients, such...
Founded in 1981
Key Executives for Emcure Pharmaceuticals Limited
Chief Operating Officer and Executive Director
Chief Executive Officer of Gennova Biopharmaceuticals Limited
Managing Director of Zuventus Healthcare Limited
Compensation as of Fiscal Year 2014.
Emcure Pharmaceuticals Limited Key Developments
Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd and Emcure Pharmaceuticals Ltd Sign Licensing Deals with Gilead Sciences Inc. to Sell a Low-Cost Version of its $1,000-a-Day Hepatitis C Drug Sovaldi
Sep 15 14
Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd. and Emcure Pharmaceuticals Ltd. are among six generic drug makers that are likely to sign licensing deals with Gilead Sciences Inc. to sell a low-cost version of its $1,000-a-day Hepatitis C drug Sovaldi. The licensing agreements will allow the generic drug companies to make and sell copies of the expensive pill for low- and middle-income countries at lower prices. By signing the licensing agreements with generic drug makers, Gilead is responding to criticism from governments and advocacy groups about the high pricing of the drug that has put it beyond the reach of most patients, particularly those in developing nations. The once-a-day pill used in combination with other antivirals is, however, the most effective therapy to counter Hepatitis C, which kills about 350,000 people a year globally.
Sanofi Partners with Emcure Pharmaceuticals for Marketing and Distribution of its Oncology Portfolio in India
Aug 6 14
Sanofi announced that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere, Jevtana, Fludara and Fasturtec, Emcure will market and distribute these brands through its Specialty Unit.
Seven Companies Sign Sub-Licensing Agreements with Medicines Patent Pool
Jul 18 14
Seven subcontracts have been signed licensing agreements with the Switzerland-based Medicines Patent Pool (MPP) to manufacture two antiretroviral drugs. The agreements involve Aurobindo, Emcure (both India), and Desano (China) manufacturing a generic version of Bristol Myers Squibb (BMS, US)'s atazanavir. The manufacturers, including Cipla, Laurus Labs, Micro Labs (all three India), and Mylan (US), have also signed agreements to manufacture ViiV Healthcare (UK)'s dolutegravir. BMS added atazanavir to the MPP in December 2013 and ViiV Healthcare included dolutegravir in the pool in April.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|